Millennium Management LLC Purchases Shares of 119,467 Selecta Biosciences Inc (SELB)

Share on StockTwits

Millennium Management LLC purchased a new position in shares of Selecta Biosciences Inc (NASDAQ:SELB) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 119,467 shares of the company’s stock, valued at approximately $1,583,000. Millennium Management LLC owned about 0.53% of Selecta Biosciences as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of the company. Rhumbline Advisers boosted its position in Selecta Biosciences by 43.7% in the second quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock valued at $222,000 after buying an additional 5,103 shares during the last quarter. Proxima Capital Management LLC purchased a new stake in Selecta Biosciences in the second quarter valued at approximately $1,075,000. BlackRock Inc. boosted its position in Selecta Biosciences by 1.6% in the first quarter. BlackRock Inc. now owns 629,978 shares of the company’s stock valued at $6,420,000 after buying an additional 9,749 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in Selecta Biosciences by 37.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 33,700 shares of the company’s stock valued at $447,000 after buying an additional 9,100 shares during the last quarter. Finally, Wasatch Advisors Inc. boosted its position in Selecta Biosciences by 9.2% in the second quarter. Wasatch Advisors Inc. now owns 235,625 shares of the company’s stock valued at $3,122,000 after buying an additional 19,803 shares during the last quarter. Institutional investors and hedge funds own 48.74% of the company’s stock.

A number of brokerages recently commented on SELB. Mizuho reiterated a “buy” rating and issued a $30.00 target price on shares of Selecta Biosciences in a research report on Wednesday, October 17th. BidaskClub lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Friday, October 5th. Stifel Nicolaus began coverage on Selecta Biosciences in a research report on Friday, September 14th. They issued a “buy” rating and a $24.00 target price on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $40.00 target price on shares of Selecta Biosciences in a research report on Wednesday, July 11th. Finally, Zacks Investment Research lowered Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, August 29th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. Selecta Biosciences presently has an average rating of “Hold” and an average target price of $27.40.

Shares of NASDAQ SELB opened at $5.24 on Wednesday. Selecta Biosciences Inc has a 52 week low of $4.74 and a 52 week high of $22.68. The company has a quick ratio of 4.96, a current ratio of 4.96 and a debt-to-equity ratio of 0.87.

Selecta Biosciences (NASDAQ:SELB) last issued its earnings results on Wednesday, August 8th. The company reported ($0.84) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.16). On average, research analysts anticipate that Selecta Biosciences Inc will post -3.07 earnings per share for the current year.

Selecta Biosciences Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Read More: How is inflation measured?

Want to see what other hedge funds are holding SELB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Selecta Biosciences Inc (NASDAQ:SELB).

Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply